Moderate hypertriglyceridemia; Moderate to severe hypertriglyceridemia; Severe hypertriglyceridemia; Prior pancreatitis; MONITORING
Fenofibrate is FDA approved for the management and treatment of hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia
New Fixed‐Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High‐Risk Patients with Mixed Dyslipidemia Versus Monotherapies -
Drug
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease
Objective To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting
Statins can be considered for patients with high triglyceride levels who have borderline (5% to 7
The median (IQR) levels of triglycerides in the IPE and the placebo group were 216
Fenofibrate is preferred if there is a need to start statin-fibrate combination therapy
35863366
Pediatrics Fenofibrate may be considered in patients on low- or moderate-intensity statin therapy (ie, statin therapy intended to lower LDL-C by <30% or ~30% to 50%, respectively) only if the benefits from atherosclerotic cardiovascular disease (ASCVD) risk reduction or triglyceride lowering when triglycerides are >500 mg/dL, outweigh the
Nonetheless, the
Statin dosages fall into three categories (low, moderate, or high) based on how much the medication can lower LDL
g
Moderate-intensity statin therapy is indicated, regardless of estimated 10-year risk, in adults 40 to 75 years of age who have diabetes Statin therapy reduces risk in adults at intermediate risk Statin dosages fall into three categories (low, moderate, or high) based on how much the medication can lower LDL
g
Fibrate use should be considered in patients with significant hypertriglyceridemia or High-, Moderate-, and Low-Intensity Statin Therapy (Used in the RCTs Reviewed by the Expert Panel)* High-Intensity Statin Therapy including statins, fibrates (fenofibrate, gemfibrozil), nicotinic acid (niacin in immediate-, slow-, or extended-release form), bile acid sequestrants, ezetimibe, omega-3 fatty acids (also called marine fatty This was a post-hoc analysis of a subset of patients who underwent PCI in the RACING trial
Cost-effectiveness plane for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary Fenofibrate and fenofibric acid are each dosed once daily without regard to meals